C4 Therapeutics
CCCC Small CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
C4 Therapeutics en bref
C4 Therapeutics (CCCC) is currently trading at 3,62 € with a market capitalization of 400 M €. The 52-week range spans from 1,19 € to 4,01 €; the current price is 9.8% below the yearly high. Year-over-year revenue growth stands at -15.0%.
💰 Dividende
C4 Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
6 analystes évaluent C4 Therapeutics (CCCC) au consensus : Achat Fort. L'objectif de cours moyen est de 11,63 €, soit un potentiel de +221.29% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 6,11 € à 26,18 €.
C4 Therapeutics : la thèse d'investissement en détail
C4 Therapeutics (CCCC) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 78.34%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 221.29% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Revenue is contracting at -15% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.93, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.
À surveiller
- The analyst consensus price target implies 221.29% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 78.34% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 24.95)
- –CA en contraction (-15% sur un an)
- –Actuellement non rentable
- –Forte volatilité (Bêta 2.93)
- –Positions vendeuses élevées (19.71%)
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to above-average price swings, elevated short interest (19.71%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy C4 Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news